Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Gilteritinib improved survival for patients with acute myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.19
Views: 196

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Prof Alexander Perl gives a press conference at AACR 2019 on the findings of the ADMIRAL trial which showed that treatment with gilteritinib improved survival for patients with relapsed or refractory acute myeloid leukaemia (AML) in comparison with standard chemotherapy.

Related videos

follow us

SIOG e-learning July 2017


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation